
Investments
18Portfolio Exits
2Funds
1Partners & Customers
5About Edwards Lifesciences
Edwards Lifesciences (NYSE: EW) is a medical equipment and devices company that designs, manufactures, and markets tissue heart valves and related repair products. The company also provides solutions in enhanced surgical recovery, clot management, infection control, anesthesia, hospital administration, annuloplasty rings, catheters, hemodynamic monitoring, and more.
Edwards Lifesciences Headquarters Location
One Edwards Way
Irvine, California, 92614,
United States
949-250-2500
Expert Collections containing Edwards Lifesciences
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Find Edwards Lifesciences in 3 Expert Collections, including Medical Devices.
Medical Devices
4,284 items
https://www.advamed.org/membership-join/membership-directory/ - excludes those without working websites.
Health Monitoring & Diagnostics
313 items
Companies developing technology for computer-aided diagnostic imaging. Companies tagged as #ComputerAidedDxImaging
Health IT
360 items
Edwards Lifesciences Web Traffic
Edwards Lifesciences Rank
Latest Edwards Lifesciences News
Aug 17, 2022
News provided by Share this article Share this article IRVINE, Calif., Aug. 17, 2022 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW ), today announced the company's PASCAL Precision transcatheter valve repair system received CE Mark for the treatment of mitral and tricuspid regurgitation (MR and TR). Edwards Lifesciences' PASCAL Precision transcatheter valve repair system "Delivering the PASCAL Precision system to clinicians in Europe marks another significant step in our partnership with physicians who treat the large population of patients with mitral and tricuspid valve disease," said Bernard J. Zovighian, Edwards' corporate vice president, transcatheter mitral and tricuspid therapies. "Edwards has a long history of innovation, and the significant advancements in the PASCAL Precision system are designed to improve clinicians' ability to provide positive outcomes for patients with both MR and TR." The PASCAL Precision system is utilized in the treatment of patients with mitral or tricuspid regurgitation, through a single delivery system. The new system is designed to enable precise navigation and implant delivery. "The PASCAL Precision system provides significant advancements in operator experience with implant delivery," said Prof Jörg Hausleiter, Professor of Medicine and the Deputy Clinic Director at the Ludwig-Maximilians University in Munich, Germany. "Having successfully treated my first patient with the PASCAL Precision system, I found it easy to operate and the improved catheter response and stability gave me greater control to place the implant exactly where I needed to." The PASCAL Precision system includes PASCAL and PASCAL Ace implants, which feature independent grasping, atraumatic clasp and closure, and implant versatility including the ability to elongate and navigate complex anatomy. The PASCAL Precision system is one of multiple transcatheter repair or replacement therapies in development by Edwards that are designed to address mitral and tricuspid valve diseases. The company is committed to transforming the treatment of mitral and tricuspid patients, supported by a robust body of clinical evidence. About Edwards Lifesciences Edwards Lifesciences is the global leader of patient-focused innovations for structural heart disease and critical care monitoring. We are driven by a passion for patients, dedicated to improving and enhancing lives through partnerships with clinicians and stakeholders across the global healthcare landscape. For more information, visit Edwards.com and follow us on Facebook, Instagram, LinkedIn, Twitter and YouTube. This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are based on estimates and assumptions made by management of the company and are believed to be reasonable, though they are inherently uncertain and difficult to predict. Our forward-looking statements speak only as of the date on which they are made, and we do not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of the statement. Investors are cautioned not to unduly rely on such forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those expressed or implied by the forward-looking statements based on a number of factors as detailed in the company's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2021, and its Quarterly Reports on Form 10-Q for the quarters ended March 31 and June 30, 2022. These filings, along with important safety information about our products, may be found at Edwards.com. Edwards, Edwards Lifesciences, the stylized E logo, Edwards PASCAL, Edwards PASCAL Precision, PASCAL, PASCAL Ace, and PASCAL Precision are trademarks of Edwards Lifesciences Corporation. All other trademarks are the property of their respective owners. SOURCE Edwards Lifesciences Corporation
Edwards Lifesciences Investments
18 Investments
Edwards Lifesciences has made 18 investments. Their latest investment was in egnite as part of their Seed on February 2, 2021.
Edwards Lifesciences Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
---|---|---|---|---|---|---|
2/10/2021 | Seed | egnite | Yes | 2 | ||
9/23/2020 | Series C - II | V-Wave | $28M | No | 2 | |
7/15/2020 | Series B | Caption Health | $53M | Yes | 5 | |
4/26/2018 | Series C | |||||
4/13/2016 | Series A - II |
Date | 2/10/2021 | 9/23/2020 | 7/15/2020 | 4/26/2018 | 4/13/2016 |
---|---|---|---|---|---|
Round | Seed | Series C - II | Series B | Series C | Series A - II |
Company | egnite | V-Wave | Caption Health | ||
Amount | $28M | $53M | |||
New? | Yes | No | Yes | ||
Co-Investors | |||||
Sources | 2 | 2 | 5 |
Edwards Lifesciences Portfolio Exits
2 Portfolio Exits
Edwards Lifesciences has 2 portfolio exits. Their latest portfolio exit was Middle Peak Medical on February 14, 2017.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
---|---|---|---|---|---|
2/14/2017 | Acquired | 1 | |||
Date | 2/14/2017 | |
---|---|---|
Exit | Acquired | |
Companies | ||
Valuation | ||
Acquirer | ||
Sources | 1 |
Edwards Lifesciences Acquisitions
13 Acquisitions
Edwards Lifesciences acquired 13 companies. Their latest acquisition was Corvia Medical on March 11, 2019.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
---|---|---|---|---|---|---|
3/11/2019 | Series E+ | $108.28M | Acquired | 2 | ||
11/29/2018 | Acquired Unit | 1 | ||||
11/26/2018 | Acquired Unit | 1 | ||||
4/18/2018 | ||||||
12/6/2017 | Series B |
Date | 3/11/2019 | 11/29/2018 | 11/26/2018 | 4/18/2018 | 12/6/2017 |
---|---|---|---|---|---|
Investment Stage | Series E+ | Series B | |||
Companies | |||||
Valuation | |||||
Total Funding | $108.28M | ||||
Note | Acquired | Acquired Unit | Acquired Unit | ||
Sources | 2 | 1 | 1 |
Edwards Lifesciences Fund History
1 Fund History
Edwards Lifesciences has 1 fund, including Social Impact Investment Fund.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
---|---|---|---|---|---|
8/2/2021 | Social Impact Investment Fund | $70M | 1 |
Closing Date | 8/2/2021 |
---|---|
Fund | Social Impact Investment Fund |
Fund Type | |
Status | |
Amount | $70M |
Sources | 1 |
Edwards Lifesciences Partners & Customers
5 Partners and customers
Edwards Lifesciences has 5 strategic partners and customers. Edwards Lifesciences recently partnered with UPS on May 5, 2020.
Date | Type | Business Partner | Country | News Snippet | Sources |
---|---|---|---|---|---|
5/4/2020 | Vendor | United States | UPS - Get Report today announced as part of its longstanding relationship with Edwards Lifesciences , it continues to help the med-tech company get necessary equipment to hospitals around the world in the ongoing battle against COVID-19 . | 3 | |
12/10/2018 | Partner | ||||
6/29/2015 | Vendor | ||||
11/24/2004 | Licensor | ||||
Licensor |
Date | 5/4/2020 | 12/10/2018 | 6/29/2015 | 11/24/2004 | |
---|---|---|---|---|---|
Type | Vendor | Partner | Vendor | Licensor | Licensor |
Business Partner | |||||
Country | United States | ||||
News Snippet | UPS - Get Report today announced as part of its longstanding relationship with Edwards Lifesciences , it continues to help the med-tech company get necessary equipment to hospitals around the world in the ongoing battle against COVID-19 . | ||||
Sources | 3 |
Edwards Lifesciences Team
14 Team Members
Edwards Lifesciences has 14 team members, including current Chief Executive Officer, Michael A. Mussallem.
Name | Work History | Title | Status |
---|---|---|---|
Michael A. Mussallem | Chief Executive Officer | Current | |
David Pyott | Chief Executive Officer | Current | |
Thomas M Abate | Chief Financial Officer | Current | |
Anita B. Bessler | Chief Financial Officer | Current | |
Arie Rand | Delta Three, Top Image Systems, and Delta Galil Industries | Chief Financial Officer | Current |
Name | Michael A. Mussallem | David Pyott | Thomas M Abate | Anita B. Bessler | Arie Rand |
---|---|---|---|---|---|
Work History | Delta Three, Top Image Systems, and Delta Galil Industries | ||||
Title | Chief Executive Officer | Chief Executive Officer | Chief Financial Officer | Chief Financial Officer | Chief Financial Officer |
Status | Current | Current | Current | Current | Current |
You May Also Like

Sensome develops micro-sensor technology for smart medical devices. Sensome's sensing technology can be integrated with any medical device to reliably identify biological tissues in contact with the device. The technology combines micrometric impedance sensors that communicate wirelessly outside the body and machine learning algorithms for accurate and predictive real-time analysis.

Bigfoot Biomedical is on a mission to improve the lives of people with insulin-requiring diabetes through the application of smart technology. Bigfoot's approach includes delivering an Internet-of-Things medical device, a cloud-connected system bundled as a monthly subscription service, to a broad population historically challenged by the high upfront costs of traditional insulin delivery hardware.

Implandata Ophthalmic Products offers the EYEMATE system to empower people to take control of glaucoma – anytime and anywhere. EYEMATE is an AI-powered, cloud-based, data-centric platform for 24/7/365 monitoring and predictive modeling of disease progression. EYEMATE's data analytics combine IOP with other vital parameters to enable personalized therapies. For people with glaucoma, this means improved quality of life and peace of mind. For eye doctors, this means improved patient care at a significantly lower cost.

CeQur is developing and commercializing advanced yet simple-to-use insulin delivery devices that make it easier for people living with type 2 diabetes to adhere to therapy and stay in control of their disease. The Company's fully optimized device, PaQ, is a three-day, wearable device that provides freedom from multiple daily insulin injections.

Nonin Medical is a medical device company. It had developed the Pulse Oximeter. Nonin Medical offers non-invasive patient monitoring systems including fingertip and tabletop pulse oximeters, regional oximetry, capnography, near-infrared spectroscopy and BIS monitors.

Withings creates smart products and apps to help people across the world take care of their health and well-being. By extending the capabilities of an object through network resources, Withings provides access to computing and storage facility at no extra cost, turning objects into smart connected devices.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.